Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 62.4 %. 33.2 % patients achieved complete remission (...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/711 |
| _version_ | 1797855495794458624 |
|---|---|
| author | S. S. Bessmeltsev L. V. Stelmashenko N. V. Stepanova K. M. Abdulkadyrov G. N. Salogub E. R. Machulaitene E. V. Kariagina |
| author_facet | S. S. Bessmeltsev L. V. Stelmashenko N. V. Stepanova K. M. Abdulkadyrov G. N. Salogub E. R. Machulaitene E. V. Kariagina |
| author_sort | S. S. Bessmeltsev |
| collection | DOAJ |
| description | We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 62.4 %. 33.2 % patients achieved complete remission (CR+n-CR). The median duration of the CR was 10.3 months. Side effects were predictable and manageable. The most common adverse events reported were asthenia, neuropathy, neutropenia and anemia. Serious adverse events were rare. These results establish VMP as a new standard of care in elderly untreated patients with multiple myeloma. VMP is highly active and well tolerated in elderly patients (> 75 years) with newly diagnosed multiple myeloma. |
| first_indexed | 2024-04-09T20:23:26Z |
| format | Article |
| id | doaj.art-b683f210247445cdb987afa77e18fa09 |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:23:26Z |
| publishDate | 2022-11-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-b683f210247445cdb987afa77e18fa092023-03-30T20:15:15ZrusABV-pressОнкогематология1818-83462413-40232022-11-01024045589Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myelomaS. S. Bessmeltsev0L. V. Stelmashenko1N. V. Stepanova2K. M. Abdulkadyrov3G. N. Salogub4E. R. Machulaitene5E. V. Kariagina6Russian Research Institute of Hematology and TransfusiologyRussian Research Institute of Hematology and TransfusiologySt.-Petersburg State Pavlov Medical UniversityRussian Research Institute of Hematology and TransfusiologySt.-Petersburg State Pavlov Medical UniversitySt.-Petersburg State Pavlov Medical UniversityCity Hospital 15We used the bortezomib (velcade) plus MP (VMP) in 24 previously untreated patients with multiple myeloma (MM). The patients had a median age of 73 years (range, 65–83 years). For patients who received velcade plus MP the overall response rate was 62.4 %. 33.2 % patients achieved complete remission (CR+n-CR). The median duration of the CR was 10.3 months. Side effects were predictable and manageable. The most common adverse events reported were asthenia, neuropathy, neutropenia and anemia. Serious adverse events were rare. These results establish VMP as a new standard of care in elderly untreated patients with multiple myeloma. VMP is highly active and well tolerated in elderly patients (> 75 years) with newly diagnosed multiple myeloma.https://oncohematology.abvpress.ru/ongm/article/view/711bortezomibmultiple myelomainitial treatmentcomplete remissionoverall survivalneuropathy |
| spellingShingle | S. S. Bessmeltsev L. V. Stelmashenko N. V. Stepanova K. M. Abdulkadyrov G. N. Salogub E. R. Machulaitene E. V. Kariagina Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma Онкогематология bortezomib multiple myeloma initial treatment complete remission overall survival neuropathy |
| title | Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| title_full | Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| title_fullStr | Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| title_full_unstemmed | Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| title_short | Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| title_sort | bortezomib velcade plus melphalan and prednisone in elderly untreated patients with multiple myeloma |
| topic | bortezomib multiple myeloma initial treatment complete remission overall survival neuropathy |
| url | https://oncohematology.abvpress.ru/ongm/article/view/711 |
| work_keys_str_mv | AT ssbessmeltsev bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT lvstelmashenko bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT nvstepanova bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT kmabdulkadyrov bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT gnsalogub bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT ermachulaitene bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma AT evkariagina bortezomibvelcadeplusmelphalanandprednisoneinelderlyuntreatedpatientswithmultiplemyeloma |